Payment overview · 2025
General Payments
$576.92
31 reported records · 15 companies
Healthcare provider profile · identity verified
James D Walker, MD
Allopathic & Osteopathic Physicians|Family Medicine · GRAND BLANC, MI · NPI 1376638973
Verified facts
What the public records show
CMS Open Payments records show James D Walker, MD received $576.92 in general payments during 2025 across 31 reported records.
PFIZER INC. accounted for 17.6% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 27 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Arexvy, Eliquis, Jardiance, Mounjaro, Ozempic, Rexulti, Rybelsus, Trelegy Ellipta.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 33 claims for Synthroid by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported AREXVY as an associated drug or biological on 47563 records involving 28786 distinct recipient NPIs. Public Medicare Part D data also shows 29 claims for Arexvy by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SHINGRIX as an associated drug or biological on 43515 records involving 26794 distinct recipient NPIs. Public Medicare Part D data also shows 36 claims for Shingrix by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 69 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 90 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 19 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 35 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 70 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Rybelsus by this doctor in 2024.
Otsuka America Pharmaceutical, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported REXULTI as an associated drug or biological on 160756 records involving 46288 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Rexulti by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 214 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| PFIZER INC. | Unresolved — no canonical attribution shown | $101.36 | 17.6% | 5 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $88.71 | 15.4% | 5 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $85.83 | 14.9% | 5 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $54.60 | 9.5% | 2 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $33.68 | 5.8% | 2 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $31.90 | 5.5% | 2 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $29.63 | 5.1% | 2 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $24.34 | 4.2% | 1 | 2025 |
| Aimmune Therapeutics, Inc. | Unresolved — no canonical attribution shown | $20.64 | 3.6% | 1 | 2025 |
| Ascensia Diabetes Care Us Inc. | Unresolved — no canonical attribution shown | $20.63 | 3.6% | 1 | 2025 |
| Paratek Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $19.40 | 3.4% | 1 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $18.38 | 3.2% | 1 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $17.43 | 3.0% | 1 | 2025 |
| Currax Pharmaceuticals LLC | Unresolved — no canonical attribution shown | $15.98 | 2.8% | 1 | 2025 |
| Ascendis Pharma Endocrinology Inc | Unresolved — no canonical attribution shown | $14.41 | 2.5% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $576.92 | 31 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $82.90 | 4 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $82.90 | 4 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $55.27 | 3 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $55.27 | 3 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Otsuka America Pharmaceutical, Inc. | $54.60 | 2 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $35.55 | 2 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $33.68 | 2 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $33.68 | 2 | 2025 |
Source payment records
|
|||||
| KISUNLA Normalized: kisunla |
Drug | Lilly USA, LLC | $33.30 | 2 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $29.63 | 2 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $29.63 | 2 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $24.34 | 1 | 2025 |
Source payment records
|
|||||
| ZENPEP Normalized: zenpep |
Drug | Aimmune Therapeutics, Inc. | $20.64 | 1 | 2025 |
Source payment records
|
|||||
| NUZYRA Normalized: nuzyra |
Drug | Paratek Pharmaceuticals, Inc. | $19.40 | 1 | 2025 |
Source payment records
|
|||||
| XHANCE Normalized: xhance |
Drug | Paratek Pharmaceuticals, Inc. | $19.40 | 1 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $18.55 | 1 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $18.46 | 1 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $18.46 | 1 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $18.46 | 1 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $18.38 | 1 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $18.10 | 1 | 2025 |
Source payment records
|
|||||
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $17.43 | 1 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Lilly USA, LLC | $16.98 | 1 | 2025 |
Source payment records
|
|||||
| CONTRAVE Normalized: contrave |
Drug | Currax Pharmaceuticals LLC | $15.98 | 1 | 2025 |
Source payment records
|
|||||
| Yorvipath Normalized: yorvipath |
Drug | Ascendis Pharma Endocrinology Inc | $14.41 | 1 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $14.26 | 1 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $13.80 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| AREXVY arexvy |
2025 | Arexvy | 2024 | 29 | exact normalized | Medicare Part D |
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 214 | exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 90 | exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 19 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 70 | exact normalized | Medicare Part D |
| REXULTI rexulti |
2025 | Rexulti | 2024 | 11 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Rybelsus rybelsus |
2025 | Rybelsus | 2024 | 13 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 69 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
33 | 11 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | AREXVY open payments reported associated product |
CMS Open Payments — General Payments 47563 supporting records · 28786 recipient NPIs · example record 1190332445 |
Arexvy · 2024 Exact normalized brand match · 1 Part D row |
29 | 29 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | SHINGRIX open payments reported associated product |
CMS Open Payments — General Payments 43515 supporting records · 26794 recipient NPIs · example record 1190332452 |
Shingrix · 2024 Exact normalized brand match · 1 Part D row |
36 | 30 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
69 | 21 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
90 | 30 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
19 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
35 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
70 | 24 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| Otsuka America Pharmaceutical, Inc. Exact reporting entity; no affiliate inference |
2025 | REXULTI open payments reported associated product |
CMS Open Payments — General Payments 160756 supporting records · 46288 recipient NPIs · example record 1227267708 |
Rexulti · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
214 | 61 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 539 | 196 |
| Levothyroxine Sodium | Levothyroxine Sodium | 390 | 153 |
| Lisinopril | Lisinopril | 357 | 133 |
| Amlodipine Besylate | Amlodipine Besylate | 319 | 121 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 287 | 62 |
| Omeprazole | Omeprazole | 278 | 107 |
| Tamsulosin Hcl | Tamsulosin Hcl | 262 | 94 |
| Simvastatin | Simvastatin | 259 | 88 |
| Metformin Hcl | Metformin Hcl | 258 | 95 |
| Gabapentin | Gabapentin | 254 | 76 |
| Metoprolol Tartrate | Metoprolol Tartrate | 225 | 87 |
| Eliquis | Apixaban | 214 | 61 |
| Losartan Potassium | Losartan Potassium | 213 | 78 |
| Pantoprazole Sodium | Pantoprazole Sodium | 200 | 78 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 188 | 70 |
| Metoprolol Succinate | Metoprolol Succinate | 166 | 57 |
| Hydrochlorothiazide | Hydrochlorothiazide | 139 | 47 |
| Allopurinol | Allopurinol | 138 | 48 |
| Lovastatin | Lovastatin | 129 | 41 |
| Furosemide | Furosemide | 128 | 43 |
| Sertraline Hcl | Sertraline Hcl | 119 | 43 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 116 | 31 |
| Enalapril Maleate | Enalapril Maleate | 116 | 40 |
| Alprazolam | Alprazolam | 113 | 42 |
| Prednisone | Prednisone | 108 | 63 |
| Atenolol | Atenolol | 104 | 34 |
| Clopidogrel | Clopidogrel Bisulfate | 104 | 40 |
| Donepezil Hcl | Donepezil Hcl | 100 | 32 |
| Escitalopram Oxalate | Escitalopram Oxalate | 96 | 34 |
| Methylprednisolone | Methylprednisolone | 94 | 83 |
| Glipizide | Glipizide | 91 | 34 |
| Jardiance | Empagliflozin | 90 | 30 |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 87 | 21 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 85 | 30 |
| Famotidine | Famotidine | 82 | 32 |
| Duloxetine Hcl | Duloxetine Hcl | 80 | 29 |
| Carvedilol | Carvedilol | 79 | 27 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 76 | 17 |
| Trazodone Hcl | Trazodone Hcl | 75 | 21 |
| Fluticasone Propionate | Fluticasone Propionate | 72 | 31 |
| Spironolactone | Spironolactone | 72 | 29 |
| Citalopram Hbr | Citalopram Hydrobromide | 70 | 19 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 70 | 27 |
| Ozempic | Semaglutide | 70 | 24 |
| Ibuprofen | Ibuprofen | 69 | 30 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 69 | 21 |
| Xarelto | Rivaroxaban | 66 | 14 |
| Hydralazine Hcl | Hydralazine Hcl | 61 | 24 |
| Meloxicam | Meloxicam | 61 | 28 |
| Tramadol Hcl | Tramadol Hcl | 61 | 20 |
| Montelukast Sodium | Montelukast Sodium | 60 | 24 |
| Finasteride | Finasteride | 59 | 17 |
| Alendronate Sodium | Alendronate Sodium | 55 | 23 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 53 | 18 |
| Torsemide | Torsemide | 53 | 18 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 51 | 35 |
| Warfarin Sodium | Warfarin Sodium | 51 | 15 |
| Amoxicillin | Amoxicillin | 49 | 40 |
| Potassium Chloride | Potassium Chloride | 49 | 20 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 45 | 16 |
| Januvia | Sitagliptin Phosphate | 44 | 16 |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 41 | 11 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 40 | 17 |
| Mirtazapine | Mirtazapine | 40 | 13 |
| Ezetimibe | Ezetimibe | 39 | 12 |
| Meclizine Hcl | Meclizine Hcl | 39 | 20 |
| Zolpidem Tartrate | Zolpidem Tartrate | 39 | 11 |
| Celecoxib | Celecoxib | 38 | 14 |
| Pravastatin Sodium | Pravastatin Sodium | 38 | 12 |
| Fenofibrate | Fenofibrate Nanocrystallized | 37 | suppressed |
| Shingrix | Varicella-Zoster Ge/As01b/Pf | 36 | 30 |
| Cephalexin | Cephalexin | 35 | 31 |
| Trulicity | Dulaglutide | 35 | suppressed |
| Bupropion Xl | Bupropion Hcl | 34 | 13 |
| Quetiapine Fumarate | Quetiapine Fumarate | 34 | 13 |
| Diazepam | Diazepam | 33 | 13 |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 33 | 18 |
| Synthroid | Levothyroxine Sodium | 33 | 11 |
| Fenofibrate | Fenofibrate | 32 | 14 |
| Fluoxetine Hcl | Fluoxetine Hcl | 32 | 14 |
| Naproxen | Naproxen | 32 | 15 |
| Tolterodine Tartrate Er | Tolterodine Tartrate | 32 | 11 |
| Azithromycin | Azithromycin | 31 | 27 |
| Doxazosin Mesylate | Doxazosin Mesylate | 31 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 31 | 25 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 30 | 13 |
| Dicyclomine Hcl | Dicyclomine Hcl | 30 | 14 |
| Nifedipine Er | Nifedipine | 30 | 11 |
| Arexvy | Rsvpref3 Antigen/As01e/Pf | 29 | 29 |
| Bumetanide | Bumetanide | 29 | 13 |
| Clobetasol Propionate | Clobetasol Propionate | 29 | 17 |
| Clonazepam | Clonazepam | 29 | suppressed |
| Estradiol | Estradiol | 29 | 13 |
| Acyclovir | Acyclovir | 28 | 15 |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 28 | suppressed |
| Glipizide Er | Glipizide | 28 | suppressed |
| Novolog Flexpen | Insulin Aspart | 28 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 26 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 26 | 20 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 26 | 15 |
| Methocarbamol | Methocarbamol | 26 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 26 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 26 | suppressed |
| Pregabalin | Pregabalin | 25 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 25 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 24 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 24 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 24 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 23 | 12 |
| Amiodarone Hcl | Amiodarone Hcl | 22 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 22 | suppressed |
| Fentanyl | Fentanyl | 21 | suppressed |
| Levetiracetam | Levetiracetam | 20 | suppressed |
| Raloxifene Hcl | Raloxifene Hcl | 20 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 20 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 20 | suppressed |
| Gemfibrozil | Gemfibrozil | 19 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 19 | suppressed |
| Mounjaro | Tirzepatide | 19 | suppressed |
| Valsartan | Valsartan | 19 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 18 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 18 | 18 |
| Atenolol-Chlorthalidone | Atenolol/Chlorthalidone | 18 | suppressed |
| Chlorthalidone | Chlorthalidone | 18 | suppressed |
| Memantine Hcl | Memantine Hcl | 18 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 18 | suppressed |
| Aripiprazole | Aripiprazole | 17 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 17 | suppressed |
| Flecainide Acetate | Flecainide Acetate | 17 | suppressed |
| Glyburide | Glyburide | 17 | suppressed |
| Morphine Sulfate Er | Morphine Sulfate | 17 | suppressed |
| Nystatin | Nystatin | 17 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 16 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 16 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 16 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 16 | suppressed |
| Mirabegron Er | Mirabegron | 16 | suppressed |
| Glimepiride | Glimepiride | 15 | suppressed |
| Metronidazole | Metronidazole | 15 | suppressed |
| Risperidone | Risperidone | 15 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 14 | 11 |
| Digoxin | Digoxin | 14 | suppressed |
| Fluconazole | Fluconazole | 14 | 11 |
| Myrbetriq | Mirabegron | 14 | suppressed |
| Nadolol | Nadolol | 14 | suppressed |
| Primidone | Primidone | 14 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 14 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 14 | suppressed |
| Enalapril-Hydrochlorothiazide | Enalapril/Hydrochlorothiazide | 13 | suppressed |
| Felodipine Er | Felodipine | 13 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 13 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 13 | suppressed |
| Irbesartan | Irbesartan | 13 | suppressed |
| Lamotrigine | Lamotrigine | 13 | suppressed |
| Latanoprost | Latanoprost | 13 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 13 | suppressed |
| Nitroglycerin | Nitroglycerin | 13 | 11 |
| Np Thyroid | Thyroid,pork | 13 | suppressed |
| Ondansetron Odt | Ondansetron | 13 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 13 | suppressed |
| Rybelsus | Semaglutide | 13 | suppressed |
| Tolterodine Tartrate | Tolterodine Tartrate | 13 | suppressed |
| Alfuzosin Hcl Er | Alfuzosin Hcl | 12 | suppressed |
| Colestipol Hcl | Colestipol Hcl | 12 | suppressed |
| Cyclosporine | Cyclosporine | 12 | suppressed |
| Hydrocortisone | Hydrocortisone | 12 | suppressed |
| Hydromorphone Hcl | Hydromorphone Hcl | 12 | suppressed |
| Inderal La | Propranolol Hcl | 12 | suppressed |
| Nortrel | Norethindrone-Ethin. Estradiol | 12 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 12 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 12 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 11 | suppressed |
| Minocycline Hcl | Minocycline Hcl | 11 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 11 | suppressed |
| Rexulti | Brexpiprazole | 11 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 11 | suppressed |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $576.92 · 31 records | PFIZER INC. | ABRYSVO, AREXVY, CAPLYTA, COMIRNATY, CONTRAVE, Cologuard Collection Kit, ELIQUIS, JARDIANCE, KISUNLA, MOUNJARO, NURTEC ODT, NUZYRA, OTEZLA, Ozempic, PREVNAR 20, QULIPTA, REPATHA, REXULTI, Rybelsus, TRELEGY ELLIPTA, UBRELVY, Wegovy, XHANCE, XIFAXAN, Yorvipath, ZENPEP, ZEPBOUND | 11 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Arexvy play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error